NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell

Current Alzheimer Research

Volumn 4, Issue 5, 2007, Pages 507-509

  Gozes, Illana ^a   Divinski, Inna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; GLUTAMINE DERIVATIVE; NEUROPROTECTIVE AGENT; NOCODAZOLE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ADRENAL MEDULLA TUMOR; ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEPOLYMERIZATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; MICROTUBULE ASSEMBLY; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CEREBRAL CORTEX; MICROTUBULES; NEURONS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS; TIME FACTORS;

EID: 37049015188     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507783018208     Document Type: Conference Paper

References (21)

1. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144: 83-90 (2003).
2. Steingart RA and Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol 252: 148-53 (2006).
3. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity- dependent neuroprotective peptide. J Neurochem 72: 1283-1293 (1999).
4. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE and Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biology 1: 193-199 (2004).
5. Gozes I, Steingart RA and Spier AD. NAP mechanisms of neuroprotection. J Mol Neurosci 24: 67-72 (2004).
6. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, et al. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 33 1085-1092 (2002).
7. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11: 353-368 (2005).
8. Lagreze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, et al. The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci 46: 933-938 (2005).
9. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR and Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 25: 225-238 (2005).
10. Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, et al. PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci 25: 7420-7428 (2005).
11. Gozes I and Spivak-Pohis I. Neurotrophic Effects of the Peptide NAP: A Novel Neuroprotective Drug Candidate. Curr Alzheimer Res 3: 197-199 (2006).
12. Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S and Gozes I. NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther 319: 332-339 (2006).
13. Divinski I, Mittelman L and Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 279: 28531-28538 (2004).
14. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA and Gozes I. Peptide neuroprotection through interaction with tubulin. J Neurochem 98: 973-984 (2006)
15. Gozes I and Littauer UZ. Tubulin microheterogeneity increases with rat brain maturation. Nature 276: 411-413 (1978).
16. Gozes I and Sweadner KJ. Multiple tubulin forms are expressed by a single neurone. Nature 294: 477-480 (1981).
17. Zemlyak I, Furman S, Brenneman DE and Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul Pept 96: 39-43 (2000).
18. Gozes I and Barnstable CJ. Monoclonal antibodies that recognize discrete forms of tubulin. Proc Natl Acad Sci USA 79: 2579-2583 (1982).
19. Gozes I and Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis 6: S37-41 (2004).
20. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003).
21. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al. Intranasal NAP Administration Reduces Accumulation of Amyloid Peptide and Tau Hyperphosphorylation in a Transgenic Mouse Model of Alzheimer's Disease at Early Pathological Stage. J Mol Neurosci 31: 165-170 (2007).